Fava et al. investigated longitudinal autoantibody profiles in patients with lupus nephritis (LN) to define serological biomarkers of histologic class. They found that baseline levels of anti-C1q and anti-double-stranded DNA antibodies may serve as noninvasive biomarkers of proliferative LN and anti-C1q antibodies may predict complete response.
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
Dr. Laurent Arnaud highlighted the latest information on systemic lupus erythematosus (SLE), including genetics, technology, treat to target, and promising findings for pulse therapy in his session at EULAR 2024.
Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.
Racial Disparities in Lupus Clinical Trial Participation By Saira Z. Sheikh, MD Why was this study done? Lupus disproportionately affects Black and Latino populations, particularly women in childbearing years. Clinical trials of patients with lupus can advance the development of therapeutics and access to better treatments, as well as improve health outcomes for patients. However,…
In a study, El Bannoudi et al. found that platelets contribute to the pathogenesis of SLE by secreting the proinflammatory platelet-associated lectin, galactoside-binding, soluble 3 binding protein (LGALS3BP), which also represents a novel biomarker of SLE clinical activity.
How does a rheumatologist treat a pregnant woman when many medications are not approved for pregnancy or safety data are limited?
Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.
Glucocorticoids remain a prominent part of care for many patients with SLE but can have toxic side effects; this EULAR 2022 session discussed one institution’s approach to lower the dosage.